PTPRC and cancer: Although further clinical validation with a larger number of CRC patients including pre-treatment and post-treatment tissues is still necessary to verify the clinical implication that CD45 represents an independent predictive biomarker of a poor clinical outcome, our retrospective study is the first to propose a positive correlation between CD45 expression in cancer cells and a poor response to CRT in CRC patients.